🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial
  2. SER-109

    Seres Therapeutics

    Clostridioides Difficile Infection

    phase 3 mab completed

    1 trial
  3. SER-109

    Seres Therapeutics

    Clostridium Difficile Infection

    phase 3 mab completed

    1 trial
  4. SEVOFLURANE, DEXMEDETOMIDINE HYDROCHLORIDE

    The George Institute

    Children under the age of 2 years having surgery lasting at least 2 hours

    phase 3 small molecule active

    1 trial
  5. SODIUM CHLORIDE , DYNE-101

    Dyne Therapeutics

    Myotonic Dystrophy Type 1

    phase 3 small molecule active

    1 trial
  6. SP, chloroquine, amodiaquine, primaquine, artesunate

    United Therapeutics Europe Ltd

    Malaria

    phase 3 small molecule completed

    1 trial
  7. SPD422 (anagrelide hydrochloride)

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial
  8. SR-A + Epratuzumab

    United Therapeutics Europe Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 3 small molecule completed

    1 trial
  9. SRP-4045

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    2 trials
  10. SRP-9003

    Sarepta Therapeutics

    Limb-girdle Muscular Dystrophy

    phase 3 mab active

    2 trials
  11. SRP-9005

    Sarepta Therapeutics

    Muscular Dystrophies, Limb-Girdle

    phase 3 mab terminated

    1 trial
  12. STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend).

    The George Institute

    Yellow fever

    phase 3 small molecule active

    1 trial
  13. STK-001, STK-001

    Stoke Therapeutics

    Dravet syndrome

    phase 3 small molecule active

    1 trial
  14. SV-BR-1-GM

    BriaCell Therapeutics

    Breast Cancer

    phase 3 mab active

    2 trials
  15. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial
  16. Saline, 0.9% Sodium Chloride Solution for Injection, JNJ-80202135, JNJ-80202135

    Janssen-Cilag International N.V.

    Hemolytic Disease of the Fetus and Newborn (HDFN)

    phase 3 small molecule active

    1 trial
  17. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial
  18. Selinexor

    Karyopharm Therapeutics Inc

    Endometrial Cancer

    phase 3 small molecule active

    2 trials
  19. Selinexor

    Karyopharm Therapeutics Inc

    Multiple Myeloma

    phase 3 small molecule active

    12 trials
  20. Selinexor

    Karyopharm Therapeutics Inc

    Dedifferentiated Liposarcoma

    phase 3 small molecule completed

    1 trial
  21. Selinexor (combination therapy)

    Karyopharm Therapeutics Inc

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial
  22. Sephience 250 mg oral powder in sachet, Sephience 1 000 mg oral powder in sachet

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial
  23. Sepiapterin

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial
  24. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Bardet-Biedl Syndrome

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources